BIOMAT Database Logo BIOMAT Database Logo

Fluorouracil, high-dose folinic acid, low-dose alpha-2b interferon and dipyridamole in the treatment of advanced colorectal cancer. A pilot study. 1991

A Zaniboni, and P Marpicati, and E Simoncini, and E Montini, and F Meriggi, and G Arcangeli, and F Bonera, and M Braga, and F Ragni, and G Marini
Servizio di Oncologia, III Medicina, Spedali Civili, Brescia, Italy.

Twenty-six patients with advanced colorectal cancer were treated with a combination based on multimodal biochemical modulation of 5-fluorouracil by means of high dose folinic acid, low-dose alpha-2b interferon and dipyridamole. The overall response rate was 42% (95% confidence intervals = 23%. 61%) with four complete remissions (15%). The median duration of response was 9 months and the median survival for responders was 15 months (all patients = 12 months). Toxic side effects included oral mucositis (grade III-IV = 38%) and a generally mild flu-like syndrome. This regimen seems active and safe enough to be compared with the combination of fluorouracil and high-dose folinic acid.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D004176 Dipyridamole A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) Antistenocardin,Apo-Dipyridamole,Cerebrovase,Cléridium,Curantil,Curantyl,Dipyramidole,Kurantil,Miosen,Novo-Dipiradol,Persantin,Persantine,Apo Dipyridamole,Novo Dipiradol
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A Zaniboni, and P Marpicati, and E Simoncini, and E Montini, and F Meriggi, and G Arcangeli, and F Bonera, and M Braga, and F Ragni, and G Marini
Randomized trial of 5-fluorouracil and high-dose folinic acid with or without alpha-2B interferon in advanced colorectal cancer.
June 1996, American journal of clinical oncology,
A Zaniboni, and P Marpicati, and E Simoncini, and E Montini, and F Meriggi, and G Arcangeli, and F Bonera, and M Braga, and F Ragni, and G Marini
High-dose folinic acid and 5-fluorouracil in advanced colorectal cancer.
January 1988, Cancer investigation,
A Zaniboni, and P Marpicati, and E Simoncini, and E Montini, and F Meriggi, and G Arcangeli, and F Bonera, and M Braga, and F Ragni, and G Marini
Treatment of advanced colorectal cancer with mitoxantrone, high dose folinic acid and fluorouracil.
October 1991, Tumori,
A Zaniboni, and P Marpicati, and E Simoncini, and E Montini, and F Meriggi, and G Arcangeli, and F Bonera, and M Braga, and F Ragni, and G Marini
[Fluorouracil and high-dose folinic acid in the treatment of advanced colorectal carcinoma].
July 1990, La Clinica terapeutica,
A Zaniboni, and P Marpicati, and E Simoncini, and E Montini, and F Meriggi, and G Arcangeli, and F Bonera, and M Braga, and F Ragni, and G Marini
Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-alpha 2b and folinic acid. The "GISCAD" experience. Italian Group for the Study of Digestive Tract Cancer.
January 1994, European journal of cancer (Oxford, England : 1990),
A Zaniboni, and P Marpicati, and E Simoncini, and E Montini, and F Meriggi, and G Arcangeli, and F Bonera, and M Braga, and F Ragni, and G Marini
High dose alpha-2b interferon + folinic acid in the modulation of 5-fluorouracil. A phase II study in advanced colorectal cancer with evidence of an unfavourable cost/benefit ratio.
February 1992, Tumori,
A Zaniboni, and P Marpicati, and E Simoncini, and E Montini, and F Meriggi, and G Arcangeli, and F Bonera, and M Braga, and F Ragni, and G Marini
5-Fluorouracil, folinic acid and cisplatin in advanced colorectal cancer: a pilot study.
August 1995, Anti-cancer drugs,
A Zaniboni, and P Marpicati, and E Simoncini, and E Montini, and F Meriggi, and G Arcangeli, and F Bonera, and M Braga, and F Ragni, and G Marini
5-Fluorouracil, leucovorin and interferon alpha 2b in advanced pancreatic cancer: a pilot study.
January 1993, Annals of oncology : official journal of the European Society for Medical Oncology,
A Zaniboni, and P Marpicati, and E Simoncini, and E Montini, and F Meriggi, and G Arcangeli, and F Bonera, and M Braga, and F Ragni, and G Marini
Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial.
April 1992, Seminars in oncology,
A Zaniboni, and P Marpicati, and E Simoncini, and E Montini, and F Meriggi, and G Arcangeli, and F Bonera, and M Braga, and F Ragni, and G Marini
Mitomycin C, 5fluorouracil and folinic acid in combination with alpha 2b interferon for advanced colorectal cancer.
December 1993, Tumori,
Copied contents to your clipboard!